Wegovy oral obesity pill launches in U.S. pharmacies after FDA approval
Novo Nordisk’s oral obesity drug Wegovy began appearing in U.S. pharmacies on Monday, Jan. 5, 2026, with the starter dose available immediately and higher doses arriving later in the week after FDA approval on Dec. 22 that also cleared it to reduce heart attack and stroke risk in obese or overweight patients. Clinical trial data showed a 13.6% average weight loss over 64 weeks on a 25 mg dose versus 2.2% for placebo (an estimated 16.6% for adherent patients who also cut calories and exercised); the pill must be taken on an empty stomach with a 30‑minute wait before eating, common side effects mirror the injectable (nausea, diarrhea, vomiting), cash prices start at $149/month for the starter dose and $299/month for higher doses (list price $1,349/month) with insurers possibly reducing patient costs to as little as $25, amid tightened insurer coverage in 2025 and pending competition from Eli Lilly.
📌 Key Facts
- The oral Wegovy pill began stocking in U.S. pharmacies on Monday, January 5, 2026; the starting dose was available immediately and higher doses were expected to arrive by the end of the week.
- The FDA approved the Wegovy pill on December 22, 2025, both for treatment of obesity and to reduce the risk of heart attack and stroke in obese or overweight patients.
- A New England Journal of Medicine trial reported an average 13.6% body weight reduction over 64 weeks on a 25 mg dose versus 2.2% with placebo; investigators estimated a 16.6% reduction for patients who adhered to the drug and also reduced calories and exercised.
- The pill must be taken on an empty stomach and patients should wait 30 minutes before eating to ensure proper absorption.
- Updated U.S. pricing: cash‑pay patients face about $149/month for the starting dose and $299/month for higher doses; the list price is $1,349/month (the same as the injectable Wegovy), and Novo Nordisk says insured patients may pay as little as $25/month.
- Insurance coverage for obesity drugs tightened in 2025 (per a GoodRx analysis), highlighting access challenges despite lower cash prices and insurer co‑pay programs.
- Common side effects—nausea, diarrhea and vomiting—are similar to those seen with the injectable formulation.
- The oral Wegovy is distinct from Novo Nordisk’s semaglutide diabetes pill Rybelsus; Eli Lilly has filed for FDA approval of a competing obesity pill and used a priority review voucher in its filing.
📊 Relevant Data
Black children exhibit higher methylation levels in the FTO gene compared to White children, which is associated with an increased risk of childhood obesity.
Racial Disparities in Methylation of NRF1, FTO, and LEPR Gene in Childhood Obesity — PMC (PubMed Central)
Racial and ethnic disparities in adult obesity prevalence are associated with variations in food and physical activity environments across U.S. counties, with stronger associations in areas with higher proportions of racial and ethnic minorities.
Genetic susceptibility to obesity, as measured by single nucleotide variants (SNVs), varies by race and ethnicity, with certain SNVs associated with higher risks of obesity-related cardiometabolic disorders in specific groups like Black participants.
Obesity-Related Genetic Susceptibility and Risk of Cardiometabolic Disorders Across US Race and Ethnicity Groups — JAMA Network Open
📰 Sources (2)
- Confirms that the Wegovy pill began stocking in U.S. pharmacies on Monday, January 5, 2026, with the starting dose available immediately and higher doses arriving by the end of the week.
- Specifies that the FDA approved the Wegovy pill for obesity on December 22 and also approved it to reduce the risk of heart attack and stroke in obese or overweight patients.
- Cites New England Journal of Medicine trial results showing a 13.6% average weight reduction over 64 weeks on a 25 mg dose versus 2.2% with placebo, with an estimated 16.6% reduction for adherent patients who also cut calories and exercised.
- Details administration requirements: the pill must be taken on an empty stomach and patients must wait 30 minutes before eating for proper absorption.
- Provides updated U.S. pricing: $149/month for the starting dose and $299/month for higher doses for cash‑pay patients; list price $1,349/month (same as the injection), with Novo Nordisk saying insured patients may pay as little as $25/month.
- Notes that insurance coverage for obesity drugs tightened in 2025 per a GoodRx analysis, contextualizing access challenges.
- Reiterates common side effects (nausea, diarrhea, vomiting) and that they are similar to the injectable formulation.
- Contrasts Wegovy pill with Novo Nordisk’s existing semaglutide diabetes pill Rybelsus, and notes Eli Lilly has filed for FDA approval of a competing obesity pill with a priority review voucher.